It has been suggested that cytomegalovirus (CMV) infection can play a significant role in the development of autoimmune diseases. We report the case of a patient with anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody associated optic neuritis in the setting of acute CMV infection. We discuss the possible role of CMV infection as a trigger for synthesis of anti-MOG antibodies.
anti-aquaporin-4-antibodies in an immunocompetent adult patient with acute CMV infection [4] ; MOG antibody status was not mentioned in that particular case report. In another study analyzing a large cohort of MOG IgG positive patients, disease onset was preceded by nonspecific infections in 11 out of 50 patients [2] . No specific infectious agent was mentioned except for one Yersinia spp. positive serology. Two other case studies reported preceding EBV and Influenza A virus infections linked to the onset of anti-MOG antibody positive myelitis [5, 6] .
Cross-reactivity between CMV and MOG peptides was observed in the Lewis rat model of experimental autoimmune encephalomyelitis [7] . Furthermore, immunization of rhesus monkeys with a CMV peptide induced the production of MOG-reactive T cells [8] . These findings provide some indirect evidence for the molecular mimicry hypothesis. In addition, CMV has been shown to drive the expansion of T-cell subpopulations with a cytotoxic and pro-inflammatory phenotype [3] . We acknowledge, however, that the formal link between CMV infection, the production of anti-MOG antibodies and the occurrence of optic neuritis remains speculative.
The transient positivity of anti-MOG antibodies (due to natural disease course and/or treatment effects) has been reported in the literature. One study found that 4 out of 22 patients exhibited a temporary decrease in MOG-IgG titers below the cut-off level [9] . In another study, up to 56% of anti-MOG antibody positive patients had no detectable antibodies during remission [10] . In our case it remains unclear whether or not the prompt initiation of antiviral therapy had an impact on the disappearance of anti-MOG antibodies. Moreover, we cannot ascertain the respective beneficial role of antiviral therapy over immunosuppression. These are important questions that would be best explored in a large prospective cohort.
Currently, there are no established guidelines regarding the treatment of anti-MOG antibody positive patients presenting after a first episode of CNS demyelination. Our patient was not started on long-term immunosuppressive treatment owing to the disappearance of anti-MOG antibodies.
Conclusion
To our knowledge, this is the first published case of anti-MOG antibody associated optic neuritis in the setting of acute CMV infection. It is likely that the optic neuritis was virally-triggered, but further research is needed to understand the role of infectious agents in the development of autoimmunity.
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